Sentences with phrase «dollar global programs»

PROFESSIONAL SUMMARY Proven leader that has EXPERTI SE managed multi-million - dollar global programs, Hands - on leader with over 30 years of delivering client organizations and budgets satisfaction and creating success through partnering at including P&L responsibility the CxO level, managing multi-million-dollar global for major client programs, organizations and budgets.

Not exact matches

That's a major global program where they're spending trillions of dollars a year and trying to build this program out for the next decade.

Medical and recreational marijuana is a multi-billion dollar global industry, with various programs either ready to be implemented or already up and running in countries like Canada, Australia, Germany, Italy, and the Czech Republic.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

LDEI Atlanta provides thousands of dollars of funding and numerous volunteer hours to local organizations each year, focused on helping organizations working in the areas of: green tables / farming, global culinary initiatives, the culinary community and programs that teach cooking, nutrition or support anti-hunger work.

Dr. Schilling galvanized the world coffee industry, worth $ 174 billion dollars per year, to recognize the potentially disastrous vulnerabilities it faced due to the lack of functional, global, open - source research and development programs that create new knowledge and technologies for the benefit of farmers.

In the wake of Kaloyeros» departure from the school, many of the projects and industry research partnerships that he had cultivated and had been negotiating fell apart or never materialized, including a Phase II of the Global 450 Consortium, a billion - dollar computer chip research program that operated at NanoFabX in partnership with the world's largest chip makers, including Samsung, GlobalFoundries, and Intel.

Because Beyond Type 1 Founders and Founding Friends pay all operational and fundraising expenses, 100 % of every dollar raised through these programs directly supports the most promising global efforts working to educate, advocate, and eventually cure type 1 diabetes.

«If we can help employees stretch their paychecks, they can use those extra dollars to participate in the 401 (k) retirement program,» Elizabeth Donnelly, a global HR managing director at Credit Suisse, tells Quartz.

The Renaissance Malmo Hotel participates in Marriott Rewards, the global guest reward program that allows members to earn their choice of points or airline miles for every dollar spent during each stay.

The application fee credit for TSA Precheck or Global Entry is worth $ 85 or $ 100 dollars depending on which program you use it for.

Over 300 industry leaders were told that Tourism Australia will build on the work it does with the global youth market as part of a major multimillion dollar international marketing push, including fresh promotion of the Working Holiday Maker Visa program.

Prepaid cards and products (such as the American Express Gift Card) as well as Corporate Purchasing Cards, Global Dollar Cards and Corporate Meeting Cards are not eligible for the Amex Pay Program.

VIVE Arts is a multi-million dollar global VR program set to advance creation and appreciation of the arts.

Other global powers touted in the document included carbon taxes, trillions of dollars annually in wealth redistribution, population - reduction schemes, and a barrage of programs dealing with everything from poverty and education to health and resource allocation.

The closing this week of the Chicago Climate Exchange, which was envisioned to be the key player in the trillion - dollar «cap and trade» market, was the final nail in the coffin of the Obama administration's effort to pass the controversial program meant to combat global warming.

Indeed, most of the improvements in our climate monitoring abilities occurred after the public interest in «global warming» began in the late 1980s, i.e., when governments began increasing funding for climate research with multi-billion dollar research programmes such as the U.S. Global Change Research Prglobal warming» began in the late 1980s, i.e., when governments began increasing funding for climate research with multi-billion dollar research programmes such as the U.S. Global Change Research PrGlobal Change Research Program.

Trump needs to dig up the roots of Paris — the 1992 U.N. climate treaty — if he is to keep his campaign promise to «stop all payments of the United States tax dollars to U.N. global warming programs.»

The Trump plan stated, «We're going to cancel the Paris Climate Agreement and stop all payments of U.S. tax dollars to U.N. global warming programs.»

He advocated rescinding «all the job - destroying Obama executive actions, including the Climate Action Plan» and said he would «cancel the Paris Climate Agreement and stop all payments of U.S. tax dollars to U.N. global warming programs.»

In Mr. Trump's energy proposal, he promises to «repeal and rescind the Climate Action Plan, cancel the Paris Climate Agreement and stop all payments of U.S. tax dollars to U.N. global warming programs» upon his election.

With my 20 years experience driving and leading organizational change, leading diverse high performance teams in managing personnel recruitment, business development, and multibillion dollar human resources programs with global impact.

Self - motivated, well - rounded project management professional with an established history of process and quality improvement having more than 10 years of experience managing successful program initiatives and large - scale projects for organizations ranging from small consulting firms to global, multi-billion dollar engineering firms looking to apply knowledge and skills in a new area of project management.

3D Personal Branding for Executives MarketWatch.com features LinkedIn job search advice from executive resume writer Laura Smith - Proulx in Boomers: Make the Most of LinkedIn Job Search Executive resume writer Laura Smith - Proulx talks with Dice.com for 2013 Cover Letter article Executive resume writer Laura Smith - Proulx quoted on Forbes.com in What To Do When Your Resume Looks Like Bad News Laura Smith - Proulx presents Rocket Fuel for Your Client Resumes: The Powerful Questioning Process panel forum at 2012 Career Directors International 2012 Summit in San Diego, CA Laura Smith - Proulx delivers 2012 National Resume Writers Association Conference panel presentation on Cover Letters: Sell It From the Heart in Charleston, SC Executive resume writer Laura Smith - Proulx accepted into Certified Job Search Strategist credentialing program Executive resume writer Laura Smith - Proulx chosen as Career Rocketeer Executive Resume Writing Expert Laura Smith - Proulx wins 3 awards, including 1st Place Best Executive Resume Writer, in global contest Laura Smith - Proulx delivers 2011 National Resume Writers Association Conference presentation on Executive Resume Writing Executive resume writer Laura Smith - Proulx earns Certified Social Media Career Strategist credential Denver resume writer Laura Smith - Proulx presents Best Practices for the 2011 Job Market to Illinois Worknet Denver - based executive resume writer Laura Smith - Proulx wins 4 global resume writing awards Laura Smith - Proulx's work selected for 2010 International Resume Writing Awards Executive resume writer Laura Smith - Proulx selected as CAREEREALISM - Approved Expert Laura Smith - Proulx among first career experts worldwide to earn Twitter Certified Career Strategist credential Laura Smith - Proulx's resume work to be featured in Barron's Designing the Perfect Resume 2010 Executive resume writer Laura Smith - Proulx wins 2009 global resume writing competition Executive resume writer Laura Smith - Proulx nominated for 2009 International Resume Writing Awards Dollar - Driven Resume Shrewd Way to Earn Interest by Laura Smith - Proulx.